<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01260883</url>
  </required_header>
  <id_info>
    <org_study_id>IND 59883</org_study_id>
    <nct_id>NCT01260883</nct_id>
    <nct_alias>NCT00014716</nct_alias>
  </id_info>
  <brief_title>Ketorolac in Postoperative Infants: Pharmacokinetics and Safety</brief_title>
  <official_title>Ketorolac in Postoperative Infants: Pharmacokinetics and Safety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infants handle ketorolac differently than adults. Study of handling of this pain medication
      given to infants following surgery. Detailed analysis of how the drug is eliminated from age
      2 months to 18 months. Compared morphine use in infants who received the drug to the group
      getting placebo. Safety testing for kidney and liver function, breathing measured by
      continuous oximetry, and any bleeding issues.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Population kinetic analysis of ketorolac stereo-isomer concentrations after single dose given
      postoperatively in infants aged 2-18 months. Safety assessments of renal and hepatic function
      tests by blood tests before and after drug administration, urinalysis pre- and post-drug,
      continuous oximetry before and for 12 hours after drug. Morphine use between active drug
      groups and placebo group in the first 24 hours after surgery was assessed as a surrogate
      analgesic measure in these non-verbal infants. A modified infant pain scale was used to
      assure consistent pain management.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clearance of S-ketorolac and R+ Ketorolac in 2-6 Month Old Infants Following Surgery</measure>
    <time_frame>24 hours following surgery</time_frame>
    <description>stereo-isomer specific clearance determined by population-based pharmacokinetic analysis (NONMEM)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Central Volume of Distribution for S- and R+ Ketorolac in 2-6 Month Old Infants</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>stereo-specific ketorolac analysis using population-based analysis (NONMEM)for ketorolac given intravenously 24 hours after surgery in 2-6 month old infants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peripheral Volume of Distribution for S- and R+ Ketorolac in 2-6 Month Old Infants</measure>
    <time_frame>24 hours post surgery</time_frame>
    <description>peripheral volume of distribution for ketorolac stereo-isomers determined by population kinetic analysis (NONMEM)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life of S- and R+ Ketorolac in 2-6 Month Old Infants</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>half-life calculated from non-compartmental analysis of ketorolac isomers in 2-6 month old infants given intravenous ketorolac following surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance of S- and R+ Ketorolac in 6-18 Month Old Infants</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>stereo-specific ketorolac clearance by population-based analysis (NONMEM)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of Distribution for Ketorolac Isomers in 6-18 Month Old Infants</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>population-based kinetic analysis of ketorolac isomers following intravenous infusion in infants after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ketorolac Stereo-isomer Volume of Distribution Peripheral in 6-18 Month Old Infants</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>population-based analysis of ketorolac stereo-isomers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life of Ketorolac Stereo-isomers in 6-18 Month Old Infants After Surgery</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>noncompartmental pharmacokinetic analysis of ketorolac stereo-isomers after intravenous infusion in postoperative infants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morphine Use in 2-6 Month Old Infants Given Ketorolac or Placebo Following Surgery</measure>
    <time_frame>first day after surgery</time_frame>
    <description>total morphine given intravenously in the 12 hours following receiving intravenous ketorolac or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Time With Room Air Oximetry Saturations Under 90% in 2-6 Month Infants</measure>
    <time_frame>12 hours after ketorolac or placebo infusion</time_frame>
    <description>continuous oximetry monitoring of room air saturation was collected for 12 hours after intravenous infusion of ketorolac or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Morphine Use in 6-18 Month Old Infants After Ketorolac or Placebo Intravenous Infusion After Surgery</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>total amount of morphine given for 12 hours after ketorolac or placebo infusion in 6-18 month old infants after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oximetry Saturation Under 90% After Ketorolac or Placebo Infusion in 6-18 Month Old Infants</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>continuous oximetry monitoring for 12 hours after ketorolac or placebo intravenous infusion in 6-18 month old infants after surgery</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Postoperative Pain in Infants</condition>
  <arm_group>
    <arm_group_label>ketorolac 1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ketorolac 1 mg/kg iv given by 10 min infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ketorolac 0.5 mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ketorolac 0.5 mg/kg iv given by 10 min infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>placebo group received D5W 10 min infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac Tromethamine 1 mg/kg</intervention_name>
    <description>Ketorolac Tromethamine 1 mg/kg infusion over 10 minutes intravenous (IV) infusion. Blood sampling in for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.</description>
    <arm_group_label>ketorolac 1 mg/kg</arm_group_label>
    <other_name>toradol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac Tromethamine 0.5 mg/kg</intervention_name>
    <description>Ketorolac Tromethamine 0.5 mg/kg infusion over 10 minutes intravenous (IV) infusion. Blood sampling for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.</description>
    <arm_group_label>ketorolac 0.5 mg/kg</arm_group_label>
    <other_name>toradol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dextrose in water (D5W) infusion over 10 minutes intravenous (IV) infusion. Blood sampling for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Dextrose in water (D5W)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-prematurely-born infants admitted to hospital following surgery ages 2-18 months,
             studied by age group 12-18 months, 6-12 months, &lt; 6 months

        Exclusion Criteria:

          -  Bleeding history in infant or family

          -  Coagulopathy

          -  Gastrointestinal bleeding history

          -  Renal or hepatic disease assessed by history and by pre-drug blood tests

          -  Premature birth (&lt;36 weeks gestation)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>18 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne M. Lynn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lynn AM, Bradford H, Kantor ED, Seng KY, Salinger DH, Chen J, Ellenbogen RG, Vicini P, Anderson GD. Postoperative ketorolac tromethamine use in infants aged 6-18 months: the effect on morphine usage, safety assessment, and stereo-specific pharmacokinetics. Anesth Analg. 2007 May;104(5):1040-51, tables of contents.</citation>
    <PMID>17456651</PMID>
  </results_reference>
  <results_reference>
    <citation>Lynn AM, Bradford H, Kantor ED, Andrew M, Vicini P, Anderson GD. Ketorolac tromethamine: stereo-specific pharmacokinetics and single-dose use in postoperative infants aged 2-6 months. Paediatr Anaesth. 2011 Mar;21(3):325-34. doi: 10.1111/j.1460-9592.2010.03484.x. Epub 2010 Dec 29.</citation>
    <PMID>21199130</PMID>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2010</study_first_submitted>
  <study_first_submitted_qc>December 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2010</study_first_posted>
  <results_first_submitted>July 20, 2011</results_first_submitted>
  <results_first_submitted_qc>August 7, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 8, 2012</results_first_posted>
  <last_update_submitted>June 4, 2013</last_update_submitted>
  <last_update_submitted_qc>June 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seattle Children's Hospital</investigator_affiliation>
    <investigator_full_name>Anne M. Lynn</investigator_full_name>
    <investigator_title>Professor, Anesthesiology and Pediatrics</investigator_title>
  </responsible_party>
  <keyword>ketorolac pharmacokinetics</keyword>
  <keyword>ketorolac stereo-isomers</keyword>
  <keyword>infants</keyword>
  <keyword>postoperative analgesia</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Infants less than 18 months of age, having surgery requiring inpatient admission, from 2001 through 2008, with normal renal and liver function, not on chronic medication , not prematurely born, were selected.</recruitment_details>
      <pre_assignment_details>If screening lab studies (blood urea nitrogen [BUN], creatinine, liver transaminase concentrations, urinalysis) were abnormal infants were excluded. If postoperative concerns precluded blood sampling or if sampling intravenous (iv) catheters did not function, infants were excluded.Of 77 infants screened, 51 infants started study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ketorolac 1 mg/kg Intravenous</title>
          <description>intravenous infusion over 10 minutes</description>
        </group>
        <group group_id="P2">
          <title>Ketorolac 0.5 mg/kg Intravenous</title>
          <description>intravenous infusion over 10 minutes</description>
        </group>
        <group group_id="P3">
          <title>Dextrose 5% in Water (D5W)</title>
          <description>intravenous infusion over 10 minutes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketorolac 1 mg/kg Intravenous</title>
          <description>intravenous infusion over 10 minutes</description>
        </group>
        <group group_id="B2">
          <title>Ketorolac 0.5 mg/kg Intravenous</title>
          <description>intravenous infusion over 10 minutes</description>
        </group>
        <group group_id="B3">
          <title>Dextrose 5% in Water (D5W)</title>
          <description>intravenous infusion over 10 minutes</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="18"/>
            <count group_id="B4" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.9" spread="3.8"/>
                    <measurement group_id="B2" value="9.4" spread="4.2"/>
                    <measurement group_id="B3" value="9" spread="3.8"/>
                    <measurement group_id="B4" value="9.1" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>while 77 infants were enrolled, exclusions during screening or lack of intravenous access precluding blood sampling eliminated 26 infants. Gender data was not collected for infants not randomized to receive drug or placebo.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clearance of S-ketorolac and R+ Ketorolac in 2-6 Month Old Infants Following Surgery</title>
        <description>stereo-isomer specific clearance determined by population-based pharmacokinetic analysis (NONMEM)</description>
        <time_frame>24 hours following surgery</time_frame>
        <population>of 25 infants aged 2-6 months enrolled, 11 were excluded. 8 received drug, 6 received placebo; this is a subset of the 77 enrolled infants (aged 2-18 months) of whom 51 completed the study. Infants receiving drug at 0.5 or 1 mg/kg were reported together, since no difference in drug handling was seen.</population>
        <group_list>
          <group group_id="O1">
            <title>S- Ketorolac Clearance</title>
            <description>stereo-specific ketorolac isomer concentrations from blood samples collected for 12 hours after ketorolac intravenous administration, analyzed by NONMEM population pharmacokinetic methodology</description>
          </group>
          <group group_id="O2">
            <title>R+ Ketorolac Clearance</title>
            <description>stereo-specific ketorolac isomer concentrations from blood samples collected for 12 hours after ketorolac intravenous administration,analyzed by population pharmacokinetic analysis (NONMEM)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>stereo-specific ketorolac isomer concentrations from blood samples collected for 12 hours after ketorolac intravenous administration,analyzed by population pharmacokinetic analysis (NONMEM)</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance of S-ketorolac and R+ Ketorolac in 2-6 Month Old Infants Following Surgery</title>
          <description>stereo-isomer specific clearance determined by population-based pharmacokinetic analysis (NONMEM)</description>
          <population>of 25 infants aged 2-6 months enrolled, 11 were excluded. 8 received drug, 6 received placebo; this is a subset of the 77 enrolled infants (aged 2-18 months) of whom 51 completed the study. Infants receiving drug at 0.5 or 1 mg/kg were reported together, since no difference in drug handling was seen.</population>
          <units>ml/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7" spread="22.8"/>
                    <measurement group_id="O2" value="6.5" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Central Volume of Distribution for S- and R+ Ketorolac in 2-6 Month Old Infants</title>
        <description>stereo-specific ketorolac analysis using population-based analysis (NONMEM)for ketorolac given intravenously 24 hours after surgery in 2-6 month old infants</description>
        <time_frame>24 hours after surgery</time_frame>
        <population>infants enrolled but did not complete protocol if abnormal laboratory studies or intravenous catheters were not functioning prior to study drug infusion. Of 77 enrolled, 51 completed study; of the 33 given ketorolac,8 were aged 2-6 months. Doses of 0.5 or 1 mg/kg were handled similarly so reported together.</population>
        <group_list>
          <group group_id="O1">
            <title>S- Ketorolac Volume Distribution, Central</title>
            <description>stereo-specific ketorolac analysis by NONMEM</description>
          </group>
          <group group_id="O2">
            <title>R+ Ketorolac Volume Distribution, Central</title>
            <description>stereo-specific ketorolac analyzed by population kinetic (NONMEM)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>stereo-specific ketorolac analyzed by population kinetic (NONMEM)</description>
          </group>
        </group_list>
        <measure>
          <title>Central Volume of Distribution for S- and R+ Ketorolac in 2-6 Month Old Infants</title>
          <description>stereo-specific ketorolac analysis using population-based analysis (NONMEM)for ketorolac given intravenously 24 hours after surgery in 2-6 month old infants</description>
          <population>infants enrolled but did not complete protocol if abnormal laboratory studies or intravenous catheters were not functioning prior to study drug infusion. Of 77 enrolled, 51 completed study; of the 33 given ketorolac,8 were aged 2-6 months. Doses of 0.5 or 1 mg/kg were handled similarly so reported together.</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1480" spread="920"/>
                    <measurement group_id="O2" value="992" spread="440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peripheral Volume of Distribution for S- and R+ Ketorolac in 2-6 Month Old Infants</title>
        <description>peripheral volume of distribution for ketorolac stereo-isomers determined by population kinetic analysis (NONMEM)</description>
        <time_frame>24 hours post surgery</time_frame>
        <population>25 infants aged 2-6 months enrolled; 11 excluded for no sampling intravenous access. 8 infants received drug, 6 received placebo. No difference in analysis of doses of 0.5 or 1 mg/kg so reported together.</population>
        <group_list>
          <group group_id="O1">
            <title>S- Ketorolac Volume Distribution, Peripheral</title>
            <description>stereo-specific ketorolac analysis by NONMEM</description>
          </group>
          <group group_id="O2">
            <title>R+ Ketorolac Volume Distribution, Peripheral</title>
            <description>stereo-specific ketorolac analyzed by population kinetic (NONMEM)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>stereo-specific ketorolac analyzed by population kinetic (NONMEM)</description>
          </group>
        </group_list>
        <measure>
          <title>Peripheral Volume of Distribution for S- and R+ Ketorolac in 2-6 Month Old Infants</title>
          <description>peripheral volume of distribution for ketorolac stereo-isomers determined by population kinetic analysis (NONMEM)</description>
          <population>25 infants aged 2-6 months enrolled; 11 excluded for no sampling intravenous access. 8 infants received drug, 6 received placebo. No difference in analysis of doses of 0.5 or 1 mg/kg so reported together.</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="341" spread="342"/>
                    <measurement group_id="O2" value="658" spread="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Half-life of S- and R+ Ketorolac in 2-6 Month Old Infants</title>
        <description>half-life calculated from non-compartmental analysis of ketorolac isomers in 2-6 month old infants given intravenous ketorolac following surgery</description>
        <time_frame>24 hours after surgery</time_frame>
        <population>total infants enrolled was 77; 26 were excluded before study procedures began. Of 51 infants completing the study, 8 infants aged 2-6 months received drug.No difference in analysis at doses of 0.5 or 1 mg/kg so reported together.</population>
        <group_list>
          <group group_id="O1">
            <title>S- Ketorolac Half-life</title>
            <description>stereo-specific ketorolac analysis by NONMEM</description>
          </group>
          <group group_id="O2">
            <title>R+ Ketorolac Half-life</title>
            <description>stereo-specific ketorolac analyzed by population kinetic (NONMEM)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>stereo-specific ketorolac analyzed by population kinetic (NONMEM)</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life of S- and R+ Ketorolac in 2-6 Month Old Infants</title>
          <description>half-life calculated from non-compartmental analysis of ketorolac isomers in 2-6 month old infants given intravenous ketorolac following surgery</description>
          <population>total infants enrolled was 77; 26 were excluded before study procedures began. Of 51 infants completing the study, 8 infants aged 2-6 months received drug.No difference in analysis at doses of 0.5 or 1 mg/kg so reported together.</population>
          <units>min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" spread="33"/>
                    <measurement group_id="O2" value="197" spread="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morphine Use in 2-6 Month Old Infants Given Ketorolac or Placebo Following Surgery</title>
        <description>total morphine given intravenously in the 12 hours following receiving intravenous ketorolac or placebo</description>
        <time_frame>first day after surgery</time_frame>
        <population>25 infants enrolled but 11 excluded. 8 received ketorolac, 6 placebo. total morphine given over 12 hours following infusion collected</population>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac 1 or 0.5 mg/kg</title>
            <description>infants receiving active drug intravenously after surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>infants receiving placebo infusion intravenously after surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Morphine Use in 2-6 Month Old Infants Given Ketorolac or Placebo Following Surgery</title>
          <description>total morphine given intravenously in the 12 hours following receiving intravenous ketorolac or placebo</description>
          <population>25 infants enrolled but 11 excluded. 8 received ketorolac, 6 placebo. total morphine given over 12 hours following infusion collected</population>
          <units>mg/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.28"/>
                    <measurement group_id="O2" value="0.08" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Time With Room Air Oximetry Saturations Under 90% in 2-6 Month Infants</title>
        <description>continuous oximetry monitoring of room air saturation was collected for 12 hours after intravenous infusion of ketorolac or placebo</description>
        <time_frame>12 hours after ketorolac or placebo infusion</time_frame>
        <population>25 infants aged 2-6 months enrolled; 11 excluded. 8 received ketorolac, 6 placebo</population>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac 1 or 0.5 mg/kg</title>
            <description>infants given ketorolac intravenously after surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>infants given placebo intravenously after surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Time With Room Air Oximetry Saturations Under 90% in 2-6 Month Infants</title>
          <description>continuous oximetry monitoring of room air saturation was collected for 12 hours after intravenous infusion of ketorolac or placebo</description>
          <population>25 infants aged 2-6 months enrolled; 11 excluded. 8 received ketorolac, 6 placebo</population>
          <units>percentage of time in 12 h after drug</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="2.1" upper_limit="7.3">Median not calculated due to small sample size</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="1.9" upper_limit="5.1">Median not calculated due to small sample size</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clearance of S- and R+ Ketorolac in 6-18 Month Old Infants</title>
        <description>stereo-specific ketorolac clearance by population-based analysis (NONMEM)</description>
        <time_frame>24 hours after surgery</time_frame>
        <population>52 infants aged 6-18 months enrolled; 15 excluded for abnormal laboratory results or intravenous sampling catheters that did not allow sampling. 25 infants aged 6-18 months received ketorolac, 12 received placebo. Doses of 0.5 or 1 mg/kg reported together since no difference found in handling.</population>
        <group_list>
          <group group_id="O1">
            <title>S- Ketorolac Clearance</title>
            <description>stereo-specific ketorolac analysis by NONMEM</description>
          </group>
          <group group_id="O2">
            <title>R+ Ketorolac Clearance</title>
            <description>stereo-specific ketorolac analyzed by population kinetic (NONMEM)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>stereo-specific ketorolac analyzed by population kinetic (NONMEM)</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance of S- and R+ Ketorolac in 6-18 Month Old Infants</title>
          <description>stereo-specific ketorolac clearance by population-based analysis (NONMEM)</description>
          <population>52 infants aged 6-18 months enrolled; 15 excluded for abnormal laboratory results or intravenous sampling catheters that did not allow sampling. 25 infants aged 6-18 months received ketorolac, 12 received placebo. Doses of 0.5 or 1 mg/kg reported together since no difference found in handling.</population>
          <units>ml/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3" spread="12.1"/>
                    <measurement group_id="O2" value="7.52" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Volume of Distribution for Ketorolac Isomers in 6-18 Month Old Infants</title>
        <description>population-based kinetic analysis of ketorolac isomers following intravenous infusion in infants after surgery</description>
        <time_frame>24 hours after surgery</time_frame>
        <population>of 52 enrolled infants aged 6-18 months, 37 completed the study. Of these, 25 received drug, 12 placebo.Doses of 0.5 or 1 mg/kg showed no difference in handling so reported together.</population>
        <group_list>
          <group group_id="O1">
            <title>S- Ketorolac Volume Distribution Central</title>
            <description>stereo-specific ketorolac analysis by NONMEM</description>
          </group>
          <group group_id="O2">
            <title>R+ Ketorolac Volume Distribution Central</title>
            <description>stereo-specific ketorolac analyzed by population kinetic (NONMEM)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>stereo-specific ketorolac analyzed by population kinetic (NONMEM)</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution for Ketorolac Isomers in 6-18 Month Old Infants</title>
          <description>population-based kinetic analysis of ketorolac isomers following intravenous infusion in infants after surgery</description>
          <population>of 52 enrolled infants aged 6-18 months, 37 completed the study. Of these, 25 received drug, 12 placebo.Doses of 0.5 or 1 mg/kg showed no difference in handling so reported together.</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2320" spread="14.6"/>
                    <measurement group_id="O2" value="1200" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ketorolac Stereo-isomer Volume of Distribution Peripheral in 6-18 Month Old Infants</title>
        <description>population-based analysis of ketorolac stereo-isomers</description>
        <time_frame>24 hours after surgery</time_frame>
        <population>52 infants aged 6-18 months enrolled; 15 excluded. 25 received ketorolac, 12 received placebo. Drug handling not different at doses of 0.5 or 1 mg/kg so reported together.</population>
        <group_list>
          <group group_id="O1">
            <title>S- Ketorolac Volume Distribution, Peripheral</title>
            <description>stereo-specific ketorolac analysis by NONMEM</description>
          </group>
          <group group_id="O2">
            <title>R+ Ketorolac Volume Distribution, Peripheral</title>
            <description>stereo-specific ketorolac analyzed by population kinetic (NONMEM)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>stereo-specific ketorolac analyzed by population kinetic (NONMEM)</description>
          </group>
        </group_list>
        <measure>
          <title>Ketorolac Stereo-isomer Volume of Distribution Peripheral in 6-18 Month Old Infants</title>
          <description>population-based analysis of ketorolac stereo-isomers</description>
          <population>52 infants aged 6-18 months enrolled; 15 excluded. 25 received ketorolac, 12 received placebo. Drug handling not different at doses of 0.5 or 1 mg/kg so reported together.</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224" spread="86"/>
                    <measurement group_id="O2" value="828" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Half-life of Ketorolac Stereo-isomers in 6-18 Month Old Infants After Surgery</title>
        <description>noncompartmental pharmacokinetic analysis of ketorolac stereo-isomers after intravenous infusion in postoperative infants</description>
        <time_frame>24 hours after surgery</time_frame>
        <population>52 infants of the 77 total were aged 6-18 months. 15 were excluded for abnormal laboratory values at screening or for lack of access to draw blood samples. 25 received drug, 12 placebo.Doses 0.5 or 1 mg/kg reported together since no difference in analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>S- Ketorolac Half-life</title>
            <description>noncompartmental ketorolac analysis</description>
          </group>
          <group group_id="O2">
            <title>R+ Ketorolac Half-life</title>
            <description>noncompartmental analysis of stereo-isomers of ketorolac</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>noncompartmental analysis of stereo-isomers of ketorolac</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life of Ketorolac Stereo-isomers in 6-18 Month Old Infants After Surgery</title>
          <description>noncompartmental pharmacokinetic analysis of ketorolac stereo-isomers after intravenous infusion in postoperative infants</description>
          <population>52 infants of the 77 total were aged 6-18 months. 15 were excluded for abnormal laboratory values at screening or for lack of access to draw blood samples. 25 received drug, 12 placebo.Doses 0.5 or 1 mg/kg reported together since no difference in analysis.</population>
          <units>min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.1" spread="42"/>
                    <measurement group_id="O2" value="238" spread="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Morphine Use in 6-18 Month Old Infants After Ketorolac or Placebo Intravenous Infusion After Surgery</title>
        <description>total amount of morphine given for 12 hours after ketorolac or placebo infusion in 6-18 month old infants after surgery</description>
        <time_frame>24 hours after surgery</time_frame>
        <population>52 infants aged 6-18 months enrolled; 15 excluded. 25 received ketorolac and 12 received placebo infusion after surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac 1 or 0.5 mg/kg</title>
            <description>infants receiving ketorolac infusion after surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo Infusion</title>
            <description>infants receiving placebo infusion after surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Total Morphine Use in 6-18 Month Old Infants After Ketorolac or Placebo Intravenous Infusion After Surgery</title>
          <description>total amount of morphine given for 12 hours after ketorolac or placebo infusion in 6-18 month old infants after surgery</description>
          <population>52 infants aged 6-18 months enrolled; 15 excluded. 25 received ketorolac and 12 received placebo infusion after surgery</population>
          <units>mg/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.5"/>
                    <measurement group_id="O2" value="2.2" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oximetry Saturation Under 90% After Ketorolac or Placebo Infusion in 6-18 Month Old Infants</title>
        <description>continuous oximetry monitoring for 12 hours after ketorolac or placebo intravenous infusion in 6-18 month old infants after surgery</description>
        <time_frame>24 hours after surgery</time_frame>
        <population>52 infants aged 6-18 months enrolled; 15 excluded. 25 received ketorolac, 12 received placebo</population>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac 1 or 0.5 mg/kg</title>
            <description>infants receiving ketorolac after surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo Infusion</title>
            <description>infants receiving placebo infusion after surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Oximetry Saturation Under 90% After Ketorolac or Placebo Infusion in 6-18 Month Old Infants</title>
          <description>continuous oximetry monitoring for 12 hours after ketorolac or placebo intravenous infusion in 6-18 month old infants after surgery</description>
          <population>52 infants aged 6-18 months enrolled; 15 excluded. 25 received ketorolac, 12 received placebo</population>
          <units>per cent time of 12 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.8"/>
                    <measurement group_id="O2" value="1" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours following surgery, monitoring for oximetry, blood loss, renal and liver function tests were done after drug infusion (active drug or placebo)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ketorolac 1 mg/kg Intravenous</title>
          <description>intravenous infusion over 10 minutes</description>
        </group>
        <group group_id="E2">
          <title>Ketorolac 0.5 mg/kg Intravenous</title>
          <description>intravenous infusion over 10 minutes</description>
        </group>
        <group group_id="E3">
          <title>Dextrose 5% in Water (D5W)</title>
          <description>intravenous infusion over 10 minutes</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anne Lynn MD</name_or_title>
      <organization>Seattle Children's Hospital</organization>
      <phone>206 987-2518</phone>
      <email>anne.lynn@seattlechildrens.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

